Anti-corona (COVID-19) polyclonal immunoglobulin (IgG) is being developed by Kamada, for the treatment of COVID-2019 infections. The hyperimmune IgG will be produced from plasma derived from donors recovered from the virus, anticipating to include antibodies to the novel Corona virus (COVID-19). The IgG is produced using the company's proprietary plasma derived IgG platform technology. Early research is underway in Israel.
In April 2020, Kamada and Kedrion Biopharma, entered into a global collaboration for the development, manufacturing and distribution of a human plasma-COVID-19 polyclonal immunoglobulin (IgG) product for treatment of coronavirus. The initial primary focus of the collaboration is to provide the product as treatment to patients in Italy, Israel and the U.S. through various clinical programs, while subsequently expanding development and commercialization efforts to additional markets. As per the agreement terms, Kedrion will provide plasma, collected at its KEDPLASMA centers, from donors who have recovered from the virus and, upon receipt of regulatory approvals, will be responsible for commercialisation of the product in the US., Europe, Australia, and South Korea. Kamada will responsible for product development, manufacturing, clinical development, with Kedrion’s support, and regulatory submissions. Kamada will also assume distribution responsibility in all territories outside of those Kedrion is responsible for. Marketing rights for the product in China will be shared by the parties. 
Key Development Milestones
As of March 2020, early research of the anti-corona (COVID-19) polyclonal immunoglobulin is underway in Israel  .
Kamada has emphasised that the development plan and manufacturing of the product are highly dependent on the availability of hyperimmune plasma and on the regulatory path to be defined with the health authorities  .